{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:11:25Z","timestamp":1792098685072,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bayer Korea","award":["17860"],"award-info":[{"award-number":["17860"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00417-019-04474-0","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T05:01:31Z","timestamp":1574053291000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"258","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ju","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Joo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"4474_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","volume":"111","author":"H Buch","year":"2004","unstructured":"Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV (2004) Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 111:53\u201361","journal-title":"Ophthalmology"},{"key":"4474_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485","journal-title":"Arch Ophthalmol"},{"key":"4474_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","volume":"16","author":"RL Avery","year":"1996","unstructured":"Avery RL, Fekrat S, Hawkins BS, Bressler NM (1996) Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16:183\u2013189","journal-title":"Retina"},{"key":"4474_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0002-9394(14)75575-8","volume":"109","author":"SR Bennett","year":"1990","unstructured":"Bennett SR, Folk JC, Blodi CF, Klugman M (1990) Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109:33\u201337","journal-title":"Am J Ophthalmol"},{"key":"4474_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","volume":"94","author":"H Glatt","year":"1982","unstructured":"Glatt H, Machemer R (1982) Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 94:762\u2013773","journal-title":"Am J Ophthalmol"},{"key":"4474_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","volume":"109","author":"CA Toth","year":"1991","unstructured":"Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd (1991) Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 109:723\u2013729","journal-title":"Arch Ophthalmol"},{"key":"4474_CR7","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1167\/iovs.08-1892","volume":"49","author":"RB Bhisitkul","year":"2008","unstructured":"Bhisitkul RB, Winn BJ, Lee OT, Wong J, Pereira Dde S, Porco TC, He X, Hahn P, Dunaief JL (2008) Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 49:4071\u20134077","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4474_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10384-017-0549-2","volume":"62","author":"JH Kim","year":"2018","unstructured":"Kim JH, Chang YS, Lee DW, Kim CG, Kim JW (2018) Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Jpn J Ophthalmol 62:54\u201362","journal-title":"Jpn J Ophthalmol"},{"key":"4474_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00417-017-3877-5","volume":"256","author":"JH Kim","year":"2018","unstructured":"Kim JH, Chang YS, Kim CG, Lee DW, Han JI (2018) Hyperpigmented spots after treatment for submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 256:469\u2013477","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4474_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"4474_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908","journal-title":"N Engl J Med"},{"key":"4474_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123:1751\u20131761","journal-title":"Ophthalmology"},{"key":"4474_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S (2018) Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol. Ophthalmology 125:1047\u20131053","journal-title":"Ophthalmology"},{"key":"4474_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.ajo.2013.01.012","volume":"155","author":"G Shienbaum","year":"2013","unstructured":"Shienbaum G, Garcia Filho CA, Flynn HW Jr, Nunes RP, Smiddy WE, Rosenfeld PJ (2013) Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol 155:1009\u20131013","journal-title":"Am J Ophthalmol"},{"key":"4474_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ophtha.2013.11.004","volume":"121","author":"JH Kim","year":"2014","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Yoo SJ, Cho HJ (2014) Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology 121:926\u2013935","journal-title":"Ophthalmology"},{"key":"4474_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2014.08.020","volume":"122","author":"MM Altaweel","year":"2015","unstructured":"Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG (2015) Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 122:391\u2013398 e395","journal-title":"Ophthalmology"},{"key":"4474_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1097\/IAE.0b013e3181dd6d8a","volume":"30","author":"MA Chang","year":"2010","unstructured":"Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM (2010) Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 30:1171\u20131176","journal-title":"Retina"},{"key":"4474_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd, Williams GA (2018) Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology 125:522\u2013528","journal-title":"Ophthalmology"},{"key":"4474_CR19","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1167\/iovs.15-17279","volume":"56","author":"Y Niwa","year":"2015","unstructured":"Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M (2015) Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci 56:6501\u20136505","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4474_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"key":"4474_CR21","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"4474_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2018.02.015","volume":"189","author":"S Kherani","year":"2018","unstructured":"Kherani S, Scott AW, Wenick AS, Zimmer-Galler I, Brady CJ, Sodhi A, Meyerle C, Solomon SD, Shaukat R, Channa R, Adeyemo O, Handa JT, Wang J, Campochiaro PA (2018) Shortest distance from fovea to subfoveal hemorrhage border is important in patients with neovascular age-related macular degeneration. Am J Ophthalmol 189:86\u201395","journal-title":"Am J Ophthalmol"},{"key":"4474_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.survophthal.2015.04.004","volume":"61","author":"D Stanescu-Segall","year":"2016","unstructured":"Stanescu-Segall D, Balta F, Jackson TL (2016) Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature. Surv Ophthalmol 61:18\u201332","journal-title":"Surv Ophthalmol"},{"key":"4474_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00417-017-3648-3","volume":"255","author":"E Fleissig","year":"2017","unstructured":"Fleissig E, Barak A, Goldstein M, Loewenstein A, Schwartz S (2017) Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique. Graefes Arch Clin Exp Ophthalmol 255:1341\u20131347","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4474_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5301\/ejo.5001074","volume":"28","author":"H Bardak","year":"2018","unstructured":"Bardak H, Bardak Y, Ercalik Y, Erdem B, Arslan G, Timlioglu S (2018) Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage. Eur J Ophthalmol 28:306\u2013310","journal-title":"Eur J Ophthalmol"},{"key":"4474_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.oret.2017.07.012","volume":"2","author":"S Sharma","year":"2018","unstructured":"Sharma S, Kumar JB, Kim JE, Thordsen J, Dayani P, Ober M, Mahmoud TH (2018) Pneumatic displacement of submacular hemorrhage with subretinal air and tissue plasminogen activator: initial United States experience. Ophthalmol Retina 2:180\u2013186","journal-title":"Ophthalmol Retina"},{"key":"4474_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001066","volume":"94","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG (2017) Characteristics of submacular hemorrhages in age-related macular degeneration. Optom Vis Sci 94:556\u2013563","journal-title":"Optom Vis Sci"},{"key":"4474_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00417-012-2038-0","volume":"251","author":"PS Muether","year":"2013","unstructured":"Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453\u2013458","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4474_CR29","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1097\/IAE.0000000000000229","volume":"34","author":"M Inoue","year":"2014","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K (2014) Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy. Retina 34:2178\u20132184","journal-title":"Retina"},{"key":"4474_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW (2016) Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 165:1\u20136","journal-title":"Am J Ophthalmol"},{"key":"4474_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00417-014-2589-3","volume":"252","author":"H Fassnacht-Riederle","year":"2014","unstructured":"Fassnacht-Riederle H, Becker M, Graf N, Michels S (2014) Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 252:1705\u20131709","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4474_CR32","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1167\/iovs.14-14610","volume":"55","author":"M Hata","year":"2014","unstructured":"Hata M, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ooto S, Tamura H, Nakanishi H, Takahashi A, Yoshikawa M, Yoshimura N (2014) Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci 55:7874\u20137880","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4474_CR33","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1038\/s41598-018-28938-1","volume":"8","author":"YI Shin","year":"2018","unstructured":"Shin YI, Sung JY, Sagong M, Lee YH, Jo YJ, Kim JY (2018) Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage. Sci Rep 8:10560","journal-title":"Sci Rep"},{"key":"4474_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/IAE.0b013e3181c969e9","volume":"30","author":"JH Jung","year":"2010","unstructured":"Jung JH, Lee JK, Lee JE, Oum BS (2010) Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy. Retina 30:865\u2013873","journal-title":"Retina"},{"key":"4474_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489\u20131506","journal-title":"Retina"},{"key":"4474_CR36","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/eye.2017.126","volume":"31","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2017) Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy. Eye (Lond) 31:1678\u20131684","journal-title":"Eye (Lond)"},{"key":"4474_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04474-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T19:21:04Z","timestamp":1605554464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04474-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4474"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04474-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"27 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jae Hui Kim: advisory board of Bayer and Novartis. The following authors have no financial disclosure: Chul Gu Kim, Dong Won Lee, Su Jin Yoo, Young Ju Lew, Han Joo Cho, Joo Yeon Kim, Seok Hyun Lee, Jong Woo Kim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of Kim\u2019s Eye Hospital (Seoul, South Korea). This study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all the patients before study enrollment. Identifying information about participants is not presented in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}